Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Miransertib (ARQ 092) Granted Fast Track Designation for the Treatment of PIK3CA-Related Overgrowth Spectrum (PROS)

ArQule, Inc. (Nasdaq: ARQL) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to miransertib (ARQ 092) for the treatment of PIK3CA-Related...

ARQL : 5.11 (+5.36%)
Implied Volatility Surging for ArQule (ARQL) Stock Options

Investors need to pay close attention to ArQule (ARQL) stock based on the movements in the options market lately.

ARQL : 5.11 (+5.36%)
ArQule to Participate in Citi's 13th Annual Biotech Conference on September 6, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, CEO, Peter Lawrence, President and COO, Brian Schwartz, CMO and Head of R&D and Marc Schegerin, Senior Vice President and Head...

ARQL : 5.11 (+5.36%)
ArQule to Participate in the Annual B. Riley FBR Healthcare Conference on September 4, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, CEO, and Dr. Brian Schwartz, CMO and Head of Research and Development, will participate in investor meetings and scientific panel...

ARQL : 5.11 (+5.36%)
ArQule to Present at the 20th Annual Global Investment Conference on September 5, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Strategy, Communication and Finance, will present at the...

ARQL : 5.11 (+5.36%)
Analysis: Positioning to Benefit within PagSeguro Digital, ChannelAdvisor, Transocean, Arcos Dorados, Precision Drilling, and ArQule -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PagSeguro Digital Ltd. (NYSE:PAGS),...

RIG : 12.65 (+2.35%)
ARQL : 5.11 (+5.36%)
ARCO : 6.75 (+2.27%)
PAGS : 28.74 (+1.13%)
ECOM : 11.05 (+0.45%)
PDS : 3.73 (-1.58%)
Medical-Drugs Stock Outlook: No Respite from Near-Term Pain

Medical-Drugs Stock Outlook: No Respite from Near-Term Pain

RDHL : 7.90 (-1.25%)
ARQL : 5.11 (+5.36%)
AERI : 57.40 (+2.14%)
GLMD : 12.91 (+0.94%)
ArQule (ARQL) Beats Q2 Earnings and Revenue Estimates

ArQule (ARQL) delivered earnings and revenue surprises of 150.00% and 78.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

ARQL : 5.11 (+5.36%)
ArQule Reports Second Quarter 2018 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2018.

ARQL : 5.11 (+5.36%)
Is Exelixis (EXEL) Poised for a Beat Again in Q2?

Exelixis (EXEL) is likely to beat earnings again in the second quarter, driven by favourable metrics. Investors will focus on the company's uptake in the first-line RCC setting, along with other updates....

ARQL : 5.11 (+5.36%)
EXEL : 16.63 (+1.16%)
RHHBY : 30.5000 (-0.16%)
BMY : 61.56 (+1.25%)
Incyte (INCY) to Report Q2 Earnings: What's in the Cards?

Incyte (INCY) has a mixed track record. Investors will focus on Jakafi sales and other pipeline updates when the company reports its Q2 results on Jul 31.

ARQL : 5.11 (+5.36%)
LLY : 105.83 (+0.09%)
INCY : 68.06 (+1.20%)
NVS : 85.46 (+0.66%)
Has ArQule (ARQL) Outpaced Other Medical Stocks This Year?

Is (ARQL) Outperforming Other Medical Stocks This Year?

ARQL : 5.11 (+5.36%)
ArQule to Report Second Quarter 2018 Financial Results on August 1, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter of 2018 before the market opens on Wednesday, August 1, 2018. The Company will hold...

ARQL : 5.11 (+5.36%)
ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

ArQule, Inc. (Nasdaq: ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their...

ARQL : 5.11 (+5.36%)
Free Pre-Market Technical Recap on ArQule and Three Additional Biotech

Stock Research Monitor: ARNA, ARWR, and ATRA

ARQL : 5.11 (+5.36%)
ARNA : 42.79 (+1.76%)
ArQule Announces Pricing of $60.5 Million Public Offering of Common Stock

ArQule, Inc. (Nasdaq: ARQL) today announced the pricing of an underwritten public offering of 11 million shares of its common stock at a price to the public of $5.50 per share. ArQule has...

ARQL : 5.11 (+5.36%)
ArQule Announces Commencement of Proposed Public Offering of Common Stock

ArQule, Inc. (Nasdaq: ARQL) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In...

ARQL : 5.11 (+5.36%)
ArQule Added to the Russell 2000(R) Index

ArQule, Inc. (Nasdaq: ARQL) today announced that it has been added to the Russell 2000(R) Index, a subset of the Russell 3000(R) Index, effective as of market closing on June 22, 2018,...

ARQL : 5.11 (+5.36%)
ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531

ArQule, Inc. (Nasdaq:ARQL) today is presenting preliminary results from the Company's Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor of...

ARQL : 5.11 (+5.36%)
ArQule to Present at The JMP Securities Life Sciences Conference on June 21, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at...

ARQL : 5.11 (+5.36%)

Van Meerten Stock Picks

Tesla According to Peter Lynch
Today's Barchart Chart of the Day will be the auto maker Tesla (TSLA).
TSLA -3.66
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

cmdty Insider - Ag Market Commentary

Today's Commentary

Corn futures are trading fractionally higher since ending the Wednesday session with most contracts 2 to 3 cents in the green. Preliminary open interest rose 17,242 contracts as harvest expands. The weekly EIA report indicated that ethanol plants pro...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar